STK11, KEAP and TP53 as Co-Mutations with Bad Prognosis - Is there a Predictive Role?
By: Ferdinandos Skoulidis, MD, PhD
Pre-Operative and Metastatic Setting Biomarkers for Immunotherapy in Lung Cancer
By: Fred Hirsch, MD
Pre-Operative and Metastatic Setting Biomarkers for Immunotherapy in Lung Cancer
By: Fred Hirsch, MD
How to Choose Front Line Therapy for Metastatic Non-Driver Mutation NSCLC
By: George R. Simon, MD, FACP, FCCP
How to Choose Front Line Therapy for Metastatic Non-Driver Mutation NSCLC
By: George R. Simon, MD, FACP, FCCP
Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance
By: George Simon, MD, FACP, FCCP
Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance
By: George Simon, MD, FACP, FCCP
Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?
By: Gerard Silvestri, MD
